Gemeinsamer Bundesausschuss

# Resolution

## of the Federal Joint Committee on a Finding in the Procedure of Routine Practice Data Collection and Evaluations according to Section 35a, paragraph 3b SGB V: Fedratinib (myelofibrosis) – Study protocol and statistical analysis plan submission

of 1 June 2023

At its session on 1 June 2023, the Federal Joint Committee (G-BA) decided the following in the procedure of routine practice data collection and evaluations according to Section 35a, paragraph 3b SGB V for the active ingredient fedratinib (myelofibrosis):

I. The routine practice data collection will not be carried out as that the pharmaceutical company has not fulfilled its obligation - by resolution of 3 November 2022 - to prepare a statistical analysis plan and study protocol prior to the implementation of the routine practice data collection.

II. The resolution will enter into force on the day of its publication on the website of the G-BA on 1 June 2023.

The justification to this resolution will be published on the website of the G-BA at www.g-ba.de.

Berlin, 1 June 2023

Federal Joint Committee (G-BA)
in accordance with Section 91 SGB V
The Chair

Prof. Hecken